Back to top
more

Theravance Biopharma (TBPH)

(Delayed Data from NSDQ)

$8.74 USD

8.74
541,902

-0.11 (-1.24%)

Updated May 20, 2022 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.08%
2Buy18.56%
3Hold10.15%
4Sell5.79%
5Strong Sell2.83%
S&P50011.24%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 253)

Industry: Medical - Drugs

Trades from $1

Company Summary

Cayman Islands-based Theravance Biopharma is a biopharmaceutical company primarily focused on discovering, developing and commercializing respiratory medicines. The company was formed following the split of the erstwhile Theravance into two listed companies in June 2014 — Innoviva, Inc. (then Theravance, Inc.) and Theravance.
 
In November 2018, the FDA approved Yupelri, a long-acting muscarinic antagonist (LAMA), as a once-daily, nebulized treatment of chronic obstructive pulmonary disease (COPD).
 
Theravance and Viatris have a collaboration for the development and commercialization of the drug. Viatris and Theravance are sharing U.S. profits and losses received in ...

General Information

Theravance Biopharma, Inc

UGLAND HOUSE SOUTH CHURCH STREET

GEORGE TOWN, E9 KY1-1104

Phone: 650-808-6000

Fax: NA

Web: http://www.theravance.com

Email: investor.relations@theravance.com

Industry Medical - Drugs
Sector Medical
Fiscal Year End December
Last Reported Quarter 3/31/2022
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

8/2/2022

EPS Information

Current Quarter EPS Consensus Estimate 0.08
Current Year EPS Consensus Estimate 0.06
Estimated Long-Term EPS Growth Rate NA
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

8/2/2022

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 8.85
52 Week High 18.83
52 Week Low 6.10
Beta 0.78
20 Day Moving Average 612,658.88
Target Price Consensus 12.00

TBPH

% Price Change
4 Week -4.59
12 Week -14.65
YTD -20.91
% Price Change Relative to S&P 500
4 Week 4.47
12 Week -4.08
YTD -3.37
Share Information
Shares Outstanding (millions) 75.90
Market Capitalization (millions) 663.38
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) 145.67
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year 80.65%
vs. Previous Quarter 44.19%
   
Sales Growth
vs. Previous Year -7.44%
vs. Previous Quarter -11.70%
   
Price Ratios
Price/Book NA
Price/Cash Flow NA
Price / Sales 12.23
ROE
3/31/22 NA
12/31/21 NA
9/30/21 NA
ROA
3/31/22 -35.41
12/31/21 -50.42
9/30/21 -53.88
Current Ratio
3/31/22 4.63
12/31/21 4.26
9/30/21 4.50
Quick Ratio
3/31/22 4.63
12/31/21 4.26
9/30/21 4.50
Operating Margin
3/31/22 -254.99
12/31/21 -360.56
9/30/21 -382.14
Net Margin
3/31/22 -268.57
12/31/21 -360.56
9/30/21 -382.14
Pre-Tax Margin
3/31/22 -268.29
12/31/21 -360.83
9/30/21 -397.03
Book Value
3/31/22 -4.63
12/31/21 -4.59
9/30/21 -4.39
Inventory Turnover
3/31/22 NA
12/31/21 NA
9/30/21 NA
Debt-to-Equity
3/31/22 NA
12/31/21 NA
9/30/21 NA
Debt to Capital
3/31/22 NA
12/31/21 NA
9/30/21 NA